

## Review Article

# Genetic Dissection of the AZF Regions of the Human Y Chromosome: Thriller or Filler for Male (In)fertility?

Paulo Navarro-Costa,<sup>1,2,3</sup> Carlos E. Plancha,<sup>2</sup> and João Gonçalves<sup>1</sup>

<sup>1</sup>Departamento de Genética, Instituto Nacional de Saúde Dr. Ricardo Jorge, 1649-016 Lisboa, Portugal

<sup>2</sup>Faculdade de Medicina de Lisboa, Instituto de Histologia e Biologia do Desenvolvimento, 1649-028 Lisboa, Portugal

<sup>3</sup>Faculdade de Medicina de Lisboa, Instituto de Medicina Molecular, 1649-028 Lisboa, Portugal

Correspondence should be addressed to Paulo Navarro-Costa, navarro-costa@fm.ul.pt

Received 17 December 2009; Accepted 23 April 2010

Academic Editor: Brynn Levy

Copyright © 2010 Paulo Navarro-Costa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The azoospermia factor (AZF) regions consist of three genetic domains in the long arm of the human Y chromosome referred to as AZFa, AZFb and AZFc. These are of importance for male fertility since they are home to genes required for spermatogenesis. In this paper a comprehensive analysis of AZF structure and gene content will be undertaken. Particular care will be given to the molecular mechanisms underlying the spermatogenic impairment phenotypes associated to AZF deletions. Analysis of the 14 different AZF genes or gene families argues for the existence of functional asymmetries between the determinants; while some are prominent players in spermatogenesis, others seem to modulate more subtly the program. In this regard, evidence supporting the notion that *DDX3Y*, *KDM5D*, *RBMY1A1*, *DAZ*, and *CDY* represent key AZF spermatogenic determinants will be discussed.

## 1. Introduction

The notion that functional determinants of spermatogenesis map to the Y chromosome (Y) was established in the 1970s [1]. Ever since the pioneering observation that deletions in the long arm of the Y chromosome (Yq) could be associated to defects in sperm production, researchers have tried to precisely map and identify such factors. In the course of this paper, a thorough genetic and functional analysis of the Y regions involved in spermatogenesis will be undertaken. These are designated as azoospermia factor (AZF) regions and they represent an area of significant interest in the field of human reproduction. In order to give added insight to this topic, the present manuscript will start with a brief overview of the major developments in the mapping of the AZF domains.

## 2. Historical Perspective on the Mapping of AZF

*2.1. The Early Years.* Following initial reports tentatively linking the loss of genetic material in Yq to azoospermia and hypogonadism, Tiepolo and Zuffardi established in 1976 the

first solid association between Y chromosome deletions and abnormal spermatogenesis [1–4]. The authors screened 1170 infertile men for karyotypic abnormalities and observed deletions removing both fluorescent (heterochromatic) and nonfluorescent (euchromatic) Yq segments in 6 azoospermic men. This association signalled the advent of a new era in the study of the Y chromosome: the identification and characterization of the Yq genetic determinants involved in spermatogenesis (Figure 1). In this regard, significant efforts were invested into mapping the azoospermia factor to a specific Yq region. These initial studies were based on the development of linear deletion interval maps using Y-specific DNA probes in samples from infertile men with cytogenetically visible Y chromosome abnormalities (illustrative examples: [5–7]). Although Bardoni and colleagues did manage to map the human spermatogenesis locus to a more precise Yq interval (Yq11.23), the early deletion mapping strategies were met with meagre success. This stemmed both from the lack of suitable DNA markers, a consequence of the highly repetitive organization of Yq; and a dependence on the relatively rare occurrence of cytogenetically visible Yq abnormalities.

2.2. *Beyond the Microscope: The Concept of Y Microdeletions.* Nevertheless, these efforts were of importance in establishing “rough drafts” of the Yq genomic map, particularly in identifying markers to be used in subsequent projects. Appropriately, Ma and colleagues in 1992 mapped a marker panel consisting of 28 DNA probes using a collection of patients with Yq structural abnormalities [8]. The real breakthrough associated to the study was the screening of “chromosomally normal” azoospermic men, leading to the identification of two deletion patterns not detectable by karyotype visualization (and therefore dubbed microdeletions). The implications of this result were paramount. Firstly, it suggested that the AZF region might in fact have a multipartite organization, with the authors referring to them as AZFa and AZFb in a subsequent report (Figure 1) [9]. Secondly, it established the notion that small Yq interstitial deletions not visualized in a standard karyotype analysis might be a causative agent of spermatogenic failure. Therefore, it became evident that the mapping of AZF could benefit from microdeletion screening programs in infertile men with apparently normal karyotypes.

Advances in molecular biology techniques, more specifically the use of PCR-based analyses of Yq genomic markers heralded a new stage in the quest for the AZF domains [10–12]. Despite the failure of some early studies in confirming the existence of two AZF regions, both the notions of multiple AZF loci and of the advantages of screening karyotypically normal infertile men (not necessarily azoospermic) gradually became entrenched in the scientific community [13–15]. The corollary of this strategy was the screening of 370 idiopathic infertile men (either azoospermic or severe oligozoospermic) with a marker panel consisting of 76 Yq sequence-tagged sites (STSs), most of them previously mapped by Vollrath and colleagues in 1992 [16]. The use of a large cohort of infertile men was crucial for the identification of less frequent microdeletion patterns that would otherwise pass undetected. This study revealed the existence of not two but three AZF regions (AZFa, AZFb, and AZFc) corresponding to three deletion intervals, each associated to a specific infertility phenotype (Figure 1). Therefore, the criterion for defining the AZF regions was above all functional since it was based on particular spermatogenic disruption phenotypes as means to delineate genomic regions. AZFa deletions were associated to complete absence of germ cells in the testis tubules (Sertoli cell-only syndrome; SCOS) and AZFb deletions to maturation arrest at the spermatocyte stage. Contrary to the azoospermia phenotype recorded in AZFa and AZFb deletions, AZFc deletions were shown to be compatible with sperm production (albeit at reduced levels) and could be transmitted to the progeny. More specifically, AZFc deletions were associated to hypospermatogenesis (abnormally decreased sperm production) that stemmed from a mixed degree of germ cell atrophy in the testis tubules [15, 17]. Although Vogt and colleagues proposed estimates of AZF sequence length and a series of gene candidates responsible for the AZFb and AZFc deletion phenotypes, the exact length, structure and gene content of the three AZF intervals would only be fully characterized in subsequent

studies. These would show that the functional partition of AZF into three individual regions was not reflected in structural terms, since the AZFb and AZFc sequences overlap (Figure 1).

2.3. *From Microdeletion Screening Programs to Sequencing the Y.* The concept of AZF microdeletion screening adopted by Vogt and colleagues was taken one step further in 1997 with the analysis of infertile men irrespectively of their spermatogenic phenotype [18]. This revealed not only that Yq microdeletions were present in ~7% of the infertile population, but also, more significantly, that a considerable variability in sperm counts was associated to such microdeletions. In fact, some microdeletion types were even detected in infertile men with normal sperm concentrations. Although it was later shown that only some partial AZF deletions might be compatible with normozoospermia, this study signalled the importance of a systematic screening of these molecular defects in the infertile population. Accordingly, AZF microdeletions are, alongside karyotype abnormalities, the most common known genetic cause of spermatogenic failure [19]. Pryor and colleagues also screened fertile men, detecting microdeletions in 2% of the individuals. This led the authors to conclude that some microdeletion patterns correspond to Y variants devoid of any obvious phenotypical consequences for male fertility. Thus, an adequate deletion screening protocol should require a validated selection of genetic markers, as well as a precise understanding of the AZF sequence in order to rule out functionally meaningless polymorphisms. Such degree of knowledge was dependent on the availability of a reference sequence for the male-specific region of the Y, which only materialized in the early 2000s [20].

After this brief overview of the historical landmarks on the identification of AZF, the following paragraphs contain a thorough genetic and functional characterization of the three intervals. For an abridged analysis of the mapping and functional properties of the AZF genes please consult Table 1 and Figure 2.

### 3. The AZFa Region of the Y Chromosome

The AZFa region totals 792 kb and was fully sequenced in 1999 [21]. AZFa maps to proximal Yq (chromosome location: ~12.9–13.7 Mb) and unlike either AZFb or AZFc, is exclusively constituted by single-copy DNA (Figure 2). The region is flanked by two human endogenous retrovirus (HERV) elements, spanning approximately 10 kb each and displaying considerable levels of sequence identity. Although the degree of similarity varies along the elements (with the distal HERV copy having an additional insertion of ~1.5 kb of transposon material—the L1 insertion), an overall sequence identity of 94% potentiates the occurrence of HERV-mediated rearrangements [22]. Accordingly, the complete AZFa deletion is the result of non-allelic homologous recombination (NAHR) between the two HERV elements [22–24]. This deletion is always associated with SCOS and is a fairly rare event, representing less than 5% of the reported

TABLE 1: Functional and genomic characterization of the AZF genes.

Gene symbol	Gene name	AZF location (amplicon unit)	mRNA expression/protein evidence (germ cell type)	Protein type	Role in the male germline	Homologous genes (location)
<i>USP9Y</i>	Ubiquitin specific peptidase 9, Y-linked	AZFa	Ubiquitous/Yes (spermatid)	Ubiquitin-specific protease	Involved in protein turnover in spermatogenesis (?)	<i>USP9X</i> (X chr.)
<i>DDX3Y</i>	DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked	AZFa	Ubiquitous/Yes (spermatogonia only)	ATP-dependent RNA helicase (deduced by similarity)	RNA metabolism in pre-meiotic germ cells (deduced by similarity)	<i>DDX3X</i> (X chr.)
<i>CYorf15A</i> <i>CYorf15B</i>	Chromosome Y open reading frame 15A/B	AZFb	Ubiquitous/No	n/a	n/a	<i>CXorf15</i> (X chr.)
<i>RPS4Y2</i>	Ribosomal protein S4, Y-linked 2	AZFb	Testis-specific/No	Ribosomal protein subunit (deduced by similarity)	Regulation of mRNA binding to the ribosome (deduced by similarity)	<i>RPS4Y1</i> (Y chr.) <i>RPS4X</i> (X chr.)
<i>EIF1AY</i>	Eukaryotic translation initiation factor 1A, Y-linked	AZFb	Ubiquitous/Yes (n/a)	Enhancer of ribosome dissociation and binding (deduced by similarity)	Regulation of translation initiation (deduced by similarity)	<i>EIF1AX</i> (X chr.)
<i>KDM5D</i>	Lysine (K)-specific demethylase 5D	AZFb	Ubiquitous/Yes (primary spermatocytes)	Demethylase of di- and tri-methylated H3K4	Chromatin remodelling in meiosis	<i>KDM5C</i> (X chr.)
<i>XKRY</i> <i>XKRY2</i>	XK, Kell blood group complex subunit-related, Y-linked/2	<i>XKRY</i> : AZFb (yel3) <i>XKRY2</i> : AZFb (yel4)	Testis-specific/No	Multipass transmembrane protein (?)	Gamete interaction (?)	—
<i>HSFY1</i> <i>HSFY2</i>	Heat shock transcription factor, Y-linked 1/2	<i>HSFY1</i> : AZFb (b5) <i>HSFY2</i> : AZFb (b6)	Testis-predominant/Yes (up to the spermatid stage)	Transcription factor	Gene expression regulation (?)	<i>HSFX1</i> (X chr.) <i>HSFX2</i> (X chr.)
<i>PRY</i> <i>PRY2</i>	PTPN13-like, Y-linked/2	<i>PRY</i> : AZFb (b1) <i>PRY2</i> : AZFb/c (b2)	Testis-specific/Yes (in some post-meiotic cells)	Signalling molecule (deduced by similarity)	Germ cell apoptosis (?)	—
<i>RBMX1A1</i>	RNA binding motif protein, Y-linked, family 1, member A1	6 functional copies in AZFb, 2 of them in amplicon units (t1 and t2)	Testis-specific/Yes (mainly meiotic and post-meiotic cells)	RNA-binding protein with protein interaction domain	RNA splicing and metabolism, signal transduction and meiotic regulation	<i>RBMX</i> (X chr.) <i>RBMXL1</i> (Chr. 1) <i>RBMXL2</i> (Chr. 11) <i>RBMXL9</i> (Chr.9)
<i>BPY2</i> <i>BPY2B</i> <i>BPY2C</i>	Basic charge, Y-linked, 2 B/C	<i>BPY2</i> : AZFb/c (g1) <i>BPY2B</i> : AZFb/c (g2) <i>BPY2C</i> : AZFc (g3)	Testis-specific/Yes (all spermatogenic stages)	Highly charged protein	Regulation of the cyto skeletal network (?)	—
<i>CDY1</i> <i>CDY2</i>	Chromodomain protein, Y-linked, 1/2	<i>CDY1A</i> : AZFb/c (yel1) <i>CDY1B</i> : AZFc (yel2) <i>CDY2A</i> : AZFb (yel3) <i>CDY2B</i> : AZFb (yel4)	Testis-specific/Yes (post-meiotic cells)	Transcriptional co-repressor with histone acetyltransferase activity	Gene expression regulation and and post-meiotic nuclear remodelling	<i>CDYL</i> (Chr. 6) <i>CDYL2</i> (Chr. 16)

TABLE 1: Continued.

Gene symbol	Gene name	AZF location (amplicon unit)	mRNA expression/protein evidence (germ cell type)	Protein type	Role in the male germline	Homologous genes (location)
<i>DAZ1</i> <i>DAZ2</i> <i>DAZ3</i> <i>DAZ4</i>	Deleted in azoospermia 1/2/3/4	<i>DAZ1</i> : AZFb/c (r1) <i>DAZ2</i> : AZFb/c (r2) <i>DAZ3</i> : AZFc (r3) <i>DAZ4</i> : AZFc (r4)	Testis-specific/Yes (spermatogonia)	RNA-binding protein with protein interaction domain	Pre-meiotic regulation of transcript transport/storage, translation initiation and protein interaction	<i>DAZL</i> (Chr. 3) <i>BOLL</i> (Chr. 2)

For appropriate references please consult the manuscript. (?):inference lacking appropriate experimental validation, n/a:not available




FIGURE 1: Mapping the azoospermia factor (AZF) region in the human Y chromosome. Heterochromatin is depicted in grey, euchromatin in blue and the two pseudoautosomal regions in black. Starting from the initial identification in 1976 of a genomic domain in Yq euchromatin regulating spermatogenesis, several studies have progressively led to a more refined mapping of this determinant. In 1991 Bardoni and colleagues mapped AZF to the distal end of Yq euchromatin, while in the next year Vogt and colleagues provided evidence for a bipartite organization (AZFa and AZFb). A major landmark was recorded in 1996, with a large-scale deletion mapping project defining three AZF regions (AZFa, AZFb and AZFc) based on the association of specific spermatogenic disruption phenotypes to nonoverlapping deletion intervals. Yet, Repping and colleagues demonstrated in 2002 that the distal end of AZFb corresponded to the proximal domain of AZFc. For complete references please consult the manuscript text.

AZF deletions [25, 26]. The low prevalence most likely stems both from limitations of the deletion mechanism (such as the lack of multiple homology domains and a relatively short recombination target), and from its considerable deleterious effect on fertility. Fittingly, the corresponding NAHR product, the AZFa duplication, is detected at a four-fold higher frequency when compared to that of the deletion [27].

AZFa contains two ubiquitously expressed genes with X homologues that escape inactivation: ubiquitin specific

peptidase 9, Y-linked (*USP9Y*) and DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked (*DDX3Y*). The precise roles these genes play in the spermatogenic process are relatively unknown, with most of the available data arising from the functional characterization of partial AZFa deletions. Interestingly, despite being ubiquitously expressed, the deletion of both genes only appears to have phenotypical consequences in the male germline, suggesting that their function is tissue-specific and/or that the X homologues can exert a rescue effect in somatic lineages.




FIGURE 2: Schematics on the genomic architecture and gene content of the reference AZFa, AZFb and AZFc regions of the human Y chromosome. Central ideogram depicts the Y chromosome with the pseudoautosomal regions represented by black boxes at the tips of the chromosome (PAR1 and PAR2, respectively), the three heterochromatic domains indicated in grey (the centromeric region, the satellite repeat array embedded in Yq euchromatin, and the Yq heterochromatic block) and euchromatin in blue. The genomic organization of the AZFa region is depicted in the top half of the figure. This region maps from approximately 12.9 to 13.7 Mb of the chromosome and contains two single copy genes: *USP9Y* and *DDX3Y* (represented in scale by two oriented triangles indicating 5'-3' polarity). AZFa is flanked by two human endogenous retrovirus (HERV) elements that mediate the occurrence of AZFa deletions via non-allelic homologous recombination. The genomic organization of the reference AZFb and AZFc regions, as defined by the occurrence of specific deletion patterns, are depicted in the bottom half of the figure. AZFb maps from approximately 18 to 24.7 Mb of the chromosome and AZFc from ~23 to ~26.7 Mb. Both regions feature multiple stretches of ampliconic sequences, represented by block arrows. The amplicons are divided in six colour-coded sequence families (yellow, blue, turquoise, green, red and grey) with each unit being coded according to a binomial notation indicative of family type and copy number [20]. The size and orientation of the arrows is representative of amplicon length and polarity, respectively. The organization of amplicons in symmetrical arrays of contiguous repeat units (palindromes P1 to P5) is represented by large triangles. AZFb is defined by the P5/proximal P1 deletion (yel3/yel1), and AZFc by the b2/b4 deletion. Single copy domains are depicted in white and the *DYZ19* satellite repeat in grey. The spacers between the two red amplicon clusters are identical between them. Transcription unit allocation to these regions is observable below the architecture map. For a more precise mapping of the genetic determinants please consult Figure 3.

### 3.1. AZFa Gene Content

3.1.1. *USP9Y*. The *USP9Y* protein is an ubiquitin-specific protease and member of the C19 cysteine peptidase family. These enzymes promote the intracellular cleavage of

ubiquitin molecules from ubiquitinated proteins [28, 29]. Appropriately, a role for *USP9Y* in the regulation of protein turnover during spermatogenesis has been proposed [30, 31]. *USP9Y* shares 91% identity with its X homologue (*USP9X*) suggesting that both target similar molecules and




FIGURE 3: Mapping and sequence organization of the transcription units located in the reference AZFb and AZFc regions of the human Y chromosome. Top schematics represent the genomic organization of the AZFb and AZFc regions, as defined by Kuroda-Kawaguchi et al., [65] and Repping et al., [20]. Block arrows represent ampliconic units and rectangles single-copy domains. The DYZ19 heterochromatic region is identified by a discontinuous grey rectangle. a- Single-copy transcription units. Direction of the triangles indicates the 5'-3' orientation of the reading frames. All these sequences map outside of the ampliconic regions. b- Multi-copy sequence families. Number of triangles per line indicates active copy number inside each sequence family. These range from two (*XKRY*, *CDY1*, *CDY2*, *HSFY*, and *PRY*) to six (*RBMY1A1*). All multi-copy transcription units bar four members of the *RBMY1A1* family map to ampliconic domains. Pseudogenes are not depicted.

may overlap functionally [32]. Studies in murine gametogenesis have shown that while *USP9X* expression starts as early as in the establishment of the primordial germ cell (PGC) population in both sexes, *USP9Y* only starts to be expressed in the male germline at the spermatid stage [32, 33]. This markedly distinct expression window hints at a temporal constrain in the regulation of *USP9Y* function, a probable consequence of its molecular targets only being present at later spermatogenic stages. Yet, available data are inconsistent with *USP9Y* being a key player in male gametogenesis. Although *USP9Y* deletions were initially thought to be exclusively associated to azoospermia and the cause of the AZFa deletion phenotype, two more recent reports demonstrate otherwise. Indeed, *USP9Y* deletions that are compatible with sperm production and with natural conception have already been identified, the latter corresponding to the complete deletion of the gene [34, 35]. Thus, published data points to *USP9Y* not being essential for male fertility, as observed in other primate lineages where the gene became inactive [36, 37]. Nevertheless, it is still premature to discard the involvement of *USP9Y* in the epistatic regulation of male gametogenesis [38].

**3.1.2. *DDX3Y*.** The *DDX3Y* protein has the hallmarks of an ATP-dependent RNA helicase belonging to the DEAD box protein family (characterized by the conserved motif Asp-Glu-Ala-Asp). The exact molecular role of *DDX3Y* is unknown, although the DEAD box proteins have been

implicated in several key processes of RNA metabolism such as secondary structure alteration, splicing, spliceosome assembly and translation initiation [39]. *DDX3Y* and its X homologue (*DDX3X*; 91.7% sequence identity) are ubiquitously expressed, with expression levels peaking in testis [40, 41]. However, the widespread presence of both transcripts in adult tissues does not directly correlate with actual protein expression since *DDX3Y*, unlike *DDX3X*, is testis-specific. An additional layer of regulation can be invoked as both genes encode for testis-specific transcripts characterized by an overall shorter length and the presence of extended untranslated regions (UTRs) [32, 42]. This specificity in transcriptional profiles most likely serves to ensure a precise expression window as *DDX3Y* is detected predominantly in the cytoplasm of spermatogonia whereas *DDX3X* is mainly detected in spermatids [40]. The divergent expression window of the two genes suggests that *DDX3Y* may represent a specialization of *DDX3X* functions for pre-meiotic developmental stages. Yet, despite differences in cell type expression, the molecular functions of *DDX3Y* and *DDX3X* are probably analogous, as evidenced by functional rescue studies in murine cell lines [41].

Taking into account data from *USP9Y* deletions as well as the regulation of *DDX3Y* function, it is tempting to consider that the absence of the latter is the main causative agent for the complete AZFa deletion phenotype. However, this hypothesis still requires the validation warranted by the unambiguous identification of *DDX3Y*-specific deletions.

#### 4. The AZFb Region of the Y Chromosome

As previously stated, the three AZF regions were defined on a functional basis: specific spermatogenic impairment phenotypes associated to specific deletion patterns. It should be noted that phenotypic specificity does not necessarily translate into genotypical individuality, as emphatically illustrated by the AZFb and AZFc regions. Although the AZFb and AZFc deletion phenotypes are noticeably different (maturation arrest and hypospermatogenesis, respectively), both sequences overlap in Yq (Figure 2). Actually, despite some early sequencing efforts pointing to a non-overlapping AZFb domain spanning 3.2 Mb, the molecular breakpoint characterization of AZFb deletions revealed not only a far larger extension for this region but also that the distal portion of the AZFb interval is part of AZFc [43, 44]. While several AZFb deletion patterns have been reported [45, 46], in the present paper the extension of this domain will be considered that defined by Repping and colleagues in 2002 [43]. According to this definition, AZFb spans a total of 6.23 Mb and maps to ~18.1–24.7 Mb of the Y. AZFb contains three single-copy regions (from the large proximal u1 domain to the more distal and considerably shorter u2 and u3 regions), a DYZ19 satellite repeat array (embedded in the u1 region) and 14 multicopy sequence units (Figure 2). These units are termed amplicons and are organized in sequence families, with intrafamily homology levels exceeding 99%. Amplicon families are defined by a specific colour code (yellow, blue, turquoise, green, red or grey), with each family member identified by a numeral. Therefore, amplicons are referred to in an *ab* notation, where *a* represents the family colour code and *b* the corresponding member number. The AZFb amplicons are divided in 6 families and of the 14 amplicon units, half of them (yel3, yel4, b5, b6, b1, t1, t2) are exclusive to AZFb, with the remaining being shared with AZFc (Figure 2). Amplicons can also be categorized by a higher-order structural organization based on symmetrical arrays of contiguous repeat units. Such arrays are designated as palindromes and are defined by a symmetry axis separating two largely identical arms constituted by single or multiple amplicon sets. AZFb contains palindromes P2 to P5, as well as the proximal part of P1. Indeed, the first description of AZFb deletions used palindrome notations to identify the NAHR recombination targets giving rise to the deletion pattern [43]. According to such notation, the complete AZFb deletion (P5/proximal P1) corresponds to the interval encompassed between amplicons yel3 and yel1.

The presence of extensive ampliconic domains in AZFb makes for very peculiar rearrangement dynamics. The complete AZFb deletion seems to occur at a similar or slightly increased rate to that of AZFa (~3 to 10 % of all Yq microdeletions), despite a much larger recombination target [47–49]. This result is somewhat counter-intuitive if we consider recombination target length as the main factor driving NAHR frequency. Nevertheless, this figure may rise five-fold if AZFb+c deletions are included, suggesting that the propensity for rearrangements may vary between amplicon units. Regarding the spermatogenic impairment phenotype of the complete AZFb deletion, patients are

azoospermic with testicular analysis revealing the presence of arrested germ cells. This maturation arrest is usually at the spermatocyte/spermatid stage, yet some very rare instances of complete spermatogenesis in a small number of testis tubules have been reported [47, 48]. Thus, the chances of finding sperm in the testis of these patients are extremely remote.

The AZFb gene content reflects the mesh of different sequence types constituting this region, with single-copy genes mapping alongside ampliconic gene families (Figure 3). A total of 5 different single-copy transcription units map to AZFb: *KDM5D* [lysine (K)-specific demethylase 5D], *EIF1AY* (eukaryotic translation initiation factor 1A, Y-linked), *RPS4Y2* (ribosomal protein S4, Y-linked 2), *CYorf15A* (chromosome Y open reading frame 15A) and *CYorf15B* (chromosome Y open reading frame 15B) [20, 43, 44]. Despite several efforts to assess their functional and regulatory properties, as a whole they can be considered as still poorly characterized.

##### 4.1. Single Copy AZFb Genes

**4.1.1. *CYorf15*.** The *CYorf15A* and *CYorf15B* sequences have an X homologue (*CXorf15*) that belongs to the taxilin family and has been linked to transcriptional regulation in osteoblasts [50]. Yet, the role of *CYorf15* sequences for either general or reproductive functions is unknown. Although *CYorf15A* and *CYorf15B* apparently encode for proteins homologous to the amino and carboxy-terminal domains of *CXorf15*, respectively, evidence for their existence is restricted to the identification of ubiquitously expressed transcripts [20].

**4.1.2. *RPS4Y2*.** *RPS4Y2* corresponds to a fairly recent duplication of the *RPS4Y* gene, the latter encoding for a ribosomal protein subunit required for mRNA binding to the ribosome [51]. Since *RPS4Y2* expression is testis-specific, a putative role in the posttranscriptional regulation of the spermatogenic program can be postulated [52]. Indeed, evidence for positive selection in the *RPS4Y2* coding sequence suggests a hypothetical acquisition of germline-specific functions. Yet, confirmation of both the existence and functional properties of the *RPS4Y2* protein are prerequisites for any further developments.

**4.1.3. *EIF1AY*.** *EIF1AY* is a ubiquitously expressed Y-linked member of the EIF-1A family—a sequence family involved in translation initiation [53]. The EIF-1A proteins are required for a high rate of protein biosynthesis since they enhance ribosome dissociation into subunits and stabilize the binding of the 43S complex (a 40S subunit, eIF2/GTP/Met-tRNAi and eIF3) to the 5' end of capped RNA [54]. *EIF1AY* has an X-homologue (*EIF1AX*) and although evidence at the protein level is available, its functions are largely deduced by similarity to *EIF1AX*. In this regard, the acquisition of male-specific regulatory features by *EIF1AY* and/or the existence of partial functional overlap with *EIF1AX* are valid hypotheses.

**4.1.4. *KDM5D*.** *KDM5D* encodes for a histone H3 lysine 4 (H3K4) demethylase that forms a protein complex with the MSH5 DNA repair factor during spermatogenesis [55, 56]. This complex locates to condensed DNA during the leptotene/zygotene stage, suggesting an involvement in male germ cell chromatin remodelling. In accordance, by demethylating di- and tri-methylated H3K4, *KDM5D* may be involved in chromosome condensation during meiosis. Such possibility fits with the instances of maturation arrest at the spermatocyte stage associated to AZFb deletions. Despite the apparently male germline-specific functions, this gene is ubiquitously expressed and is homologous to *KDM5C*, an X-borne gene associated to X-linked mental retardation [57–60].

**4.2. Multicopy AZFb Genes.** Due to the presence of ampliconic sequences AZFb contains a set of 7 different multicopy gene families: *XKRY* (XK, Kell blood group complex subunit-related, Y-linked), *HSFY* (heat shock transcription factor, Y-linked), *RBMY1A1* (RNA binding motif protein, Y-linked, family 1, member A1), *PRY* (PTPN13-like, Y-linked) *CDY* (chromodomain protein, Y-linked), *BPY2* (basic charge, Y-linked, 2), and *DAZ* (deleted in azoospermia). The members of these gene families make for a total of 20 transcription units in the reference AZFb sequence. Since several of them also map to AZFc, only genes with functional copies exclusively located in AZFb will be analysed in this section.

**4.2.1. *XKRY*.** The *XKRY* gene is expressed specifically in testis and maps to the yellow-coded amplicon family. Although protein evidence is still lacking, sequence analysis suggests that the two active copies of *XKRY* (mapping to *yel3* and *yel4*) encode for a multipass transmembrane transport protein similar to the XK protein. The latter locates to neuromuscular and hematopoietic cell membranes, with XK mutations causing specific disruption phenotypes [61–63]. However, a role for *XKRY* in spermatogenesis has yet to be validated despite tentative links to the fertilization process [64].

**4.2.2. *HSFY*.** *HSFY* encodes for a member of the heat shock factor family of transcriptional activators and displays testis-predominant expression. This gene maps to the blue amplicons with the two active copies located in b5 and b6. *HSFY* is subjected to alternative splicing, generating 3 different protein-coding transcripts with varying expression patterns [66]. *HSFY* has been identified in spermatogenic cells up to the spermatid stage and in Sertoli cells [67]. The protein's stage-dependent translocation from the cytoplasm to the nucleus is suggestive of a developmentally regulated functional window, consistent with its role as a transcription factor. Nevertheless, as previously argued, the *HSFY* polyclonal antiserum used in the former study might have detected epitopes from the more widely expressed X homologues (*HSFX1/2*) [32]. In this regard, a subsequent report by the same team established that the mouse orthologue of *HSFY* is predominantly expressed in round spermatids [68].

Regardless of several uncertainties on the exact function and regulation of *HSFY*, a role in spermatogenesis has already been proposed based on observations in animal models and in infertile males. More specifically, Vinci and colleagues detected a partial AZFb deletion purportedly only affecting the functional copies of *HSFY* in an azoospermic man [69]. Yet, it should be noted that the heritability of the deletion was unknown. More recently, *HSFY* protein levels in spermatogenic cells were shown to be decreased in samples with maturation arrest, associating once again this gene to the regulation of male gametogenesis [70].

**4.2.3. *PRY*.** The *PRY* gene copies map to the blue amplicons, with the two functional units being restricted to b1 and b2. These are designated as *PRY* and *PRY2*, respectively, and encode for a gene product with a low degree of similarity to protein tyrosine phosphatase, nonreceptor type 13. The latter corresponds to a signalling molecule involved in the regulation of a myriad of cellular processes, particularly in programmed cell death (illustrative example: [71]). *PRY* and *PRY2* display testis-specific expression and additional regulation via alternative splicing [72]. Nevertheless, the alternative transcript seems to correspond to a nonfunctional isoform since it contains a premature stop codon truncating the product at about half. The expression of *PRY* in germ cells is irregular, with the protein being detected only in a few sperm and spermatids [73]. Interestingly, both transcript and protein levels were shown to be higher in the defective germ cell fraction of the ejaculate. Furthermore, *PRY* levels are increased in ejaculated sperm obtained from men with abnormal semen parameters, suggesting a link between its expression and defective spermatogenesis. Appropriately, a role for *PRY* in male germ cell apoptosis has been suggested based on the observation that approximately 40% of *PRY*-positive cells show DNA fragmentation. Yet, as acknowledged by the authors of the paper, results were insufficient to fully back the claim. Regardless of such considerations, available evidence points to a postmeiotic expression of *PRY* in restricted subsets of developing germ cells.

**4.2.4. *RBMY1A1*.** The *RBMY1A1* gene family was identified in the early 1990s [13]. At the time, the functional properties of the then dubbed Y chromosome RNA recognition motif gene (*YRRM*) made it the first candidate azoospermia factor. Although *RBMY1A1* is present in multiple copies along the Y chromosome, the six functional units cluster to the AZFb amplicons [74, 75]. This complex arrangement, characterized by an extensive array of *RBMY1A1* pseudogenes and sub-families, had thwarted initial attempts to precisely map this determinant [76, 77]. *RBMY1A1* is part of the RBM gene family that also includes an X homologue (RBMX) and a set of autosomal retrogene-derived copies of *RBMX* (of these only *RBMXL1*, *RBMXL2* and *RBMXL9* are expressed, and protein evidence is only available for *RBMXL2*) (for a review: [78]). Unlike its ubiquitously expressed X homologue, *RBMY1A1* is expressed solely in male germ cells, with the protein displaying a nuclear location [75]. The main feature of the RBM family is the presence of a N-terminal RNA

recognition motif (RRM) responsible for the interaction with target RNA molecules [74, 79]. In this regard, RBM family members display characteristics of canonical RNA-binding proteins involved in nuclear RNA processing. In fact, this gene has been linked to the storage and transport of mRNA from the nucleus during spermatogenesis [80]. Contrasting with the other RBM genes, *RBMY1A1* also contains a C-terminal protein interaction repeat domain enriched in serine, arginine, glycine, and tyrosine (SRGY) [78]. This serves as a probable regulatory region for the modulation of *RBMY1A1* function.

The nuclear localization of *RBMY1A1* is pinpointed to domains enriched in pre-mRNA splicing components, as evidenced in prophase I nuclei [81]. In accordance, efforts to identify *RBMY1A1*-interacting proteins have shown that pre-mRNA splicing regulators, particularly the SR and the SR-related proteins, are *bona fide* partners [82, 83]. These ubiquitously expressed factors also contain RRM domains, therefore their functional modulation via *RBMY1A1* interaction emerges as a distinct possibility [84]. Additionally, *RBMY1A1* may modulate cellular processes other than splicing regulation and mRNA metabolism since it has been shown to interact with the STAR and T-STAR proteins [85]. These act not only as splicing regulators but also as members of signal transduction pathways involved in cell cycle control. In this regard, *RBMY1A1* can be involved in several aspects of meiotic and premeiotic regulation via the establishment of multiple protein complexes. Interestingly, the male germ cell-specific expression of *RBMY1A1* is also mimicked by the autosomal *RBMXL2* gene. In this case the nuclear localization of the protein during and immediately after meiosis is suggestive of meiotic specialization [86]. In accordance, haploinsufficiency of the murine *RBMXL2* orthologue results in abnormal spermatogenesis in animal models [87].

The identification of the RNA targets of *RBMY1A1* has been partially successful. It is believed that the RRM domain can bind RNA at both high and low affinity, making the characterization of target molecules complex [78]. Furthermore, the protein has an unique two-step mechanism for RNA recognition that starts with a sequence-specific interaction with the target molecule before eliciting a conformational modification [88]. This complex mechanism warrants *RBMY1A1* a significant plasticity in terms of RNA partners. Studies in murine models have identified 12 different potential mRNA targets for *RBMY1A1*, most of them expressed in testis starting from the neonatal period [89]. Interestingly, the protein seems to be able to bind to its own alternative transcript, suggesting a complex regulatory network. The existence of alternative *RBMY1A1* transcripts has also been detected in humans [90].

All the aforementioned properties seem to indicate that the disruption of *RBMY1A1* plays a significant role in the AZFb deletion phenotype. In reality, both its expression pattern and putative role in male germ cell development support the notion that *RBMY1A1* deletions perturb the meiotic program. Similarly, the disruption of *KDM5D* may also contribute to the deletion phenotype. In fact, *RBMY1A1* and *KDM5D* are located in the germ cell nucleus during

prophase I, suggesting involvement in meiotic orchestration. While this regulation may be directly exerted by *KDM5D* (via changes in chromatin structure), the role of *RBMY1A1* might be mediated by effector proteins or by transcriptional regulation of mRNA targets.

Regardless of the actual contribution of the AZFb genes for the maturation arrest phenotype, a predominantly structural effect of the AZFb deletion on meiotic progression cannot be discarded. The removal of such a large stretch of Yq chromatin (~6.23 Mb) may result in X-Y pairing impairment during meiosis and lead to meiotic breakdown. This effect has already been identified in patients with AZFb+c deletions [91]. In such cases, a significant decrease in spermatocyte X-Y bivalent formation was recorded, with only 29% of the cells having juxtaposed telomere signals. It can be argued that the lower rate of sex chromosome pairing arises from DNA conformational changes that undermine meiotic efficiency. However, it is impossible to dissociate the effect of gene loss from the observed pairing impairment, particularly since we are dealing with genes involved in cell cycle progression. Therefore, and in light of all evidence, the maturation arrest phenotype associated to AZFb deletions most probably stems from a combination of genetic disruption with structural defects in the chromosome.

## 5. The AZFc Region of the Y Chromosome

The AZFc region is one of the most remarkable domains of the human genome, displaying a structural and functional intricacy only paralleled by the major histocompatibility complex in chromosome 6. The sequencing of AZFc represented a monumental effort based on laborious data compilation and inventive analytical tools [65]. Paradoxically, the effort put into sequencing AZFc revealed that the obtained sequence corresponds to just one of the plethora of expected genomic variants in the Y chromosome population. This observation arises from the fact that AZFc is almost exclusively constituted by amplicons. Indeed, the extensive homology between intra-family ampliconic units is a fertile substrate for large-scale AZFc structural rearrangements (deletions, duplications and inversions) as well as more subtle sequence modifications. Yet, both the molecular drivers and phenotypical consequences of AZFc variability fall outside the scope of the present review, having been thoroughly discussed elsewhere [92].

*5.1. Genomic Assembly of AZFc.* Approximately 95% of the reference AZFc sequence is constituted by ampliconic units belonging to five different colour-coded families (blue, green, red, grey and yellow). The remainder corresponds to a duplicated spacer for the red amplicons (present in the two red amplicon clusters) and a single copy domain (u3) similar to other Y regions (Figure 2). Structurally, the region contains one large (P1) and one smaller (P2) palindrome, as well as the b2-u3-g1 segment. Different models for the genomic assembly of the reference AZFc structure have been proposed. A simple, two-step model states that the palindromes arose from supragenetic tandem duplication

followed by inversion [65]. Traces of such events have already been detected in the P1 palindrome, where *Alu* elements were probably involved in a large-scale duplication prior to an IR (inverted repeat)-mediated inversion. Recently, a more complex model for the progressive assembly of the AZFc ampliconic organization was proposed. The model states that 3 major waves of amplicon acquisition were required for the establishment of AZFc, starting from a basal structure constituted by the blue, turquoise and the distal part of the yellow amplicons [93]. In the first wave, the green and red amplicons were transposed; in the second the middle segment of the yellow amplicon was acquired, and in the third both the proximal yellow amplicon segment and the grey amplicon were transposed. In parallel with these acquisition waves, other molecular processes such as deletions, duplications and inversions shaped AZFc by operating on the progressively acquired blocks. A limitation to this model is the assumption that the ampliconic families of the ancestral AZFc state are identical to those of the reference sequence. This limitation is also evident when calculating the minimum-mutation history of AZFc architectures [94]. According to the most parsimonious model, the ancestral AZFc architecture was already multicopy, with the majority of the observed diversity arising from sequence inversions (and to a lesser degree from deletions and duplications) in the ancestral sequence.

In clinical terms, men with complete AZFc deletions have variable seminal and testicular phenotypes, with sperm production levels ranging from azoospermia to severe oligozoospermia (but rarely exceeding 1 million sperm/ml) [16, 47, 48]. Although in these patients the presence of sperm in the ejaculate is a frequent event (in ~50 to 60% of the cases), natural conception is extremely rare due to low sperm counts [16, 95–101]. The variable phenotype associated to these deletions suggests an intricate regulation of the AZFc genetic determinants, making this region particularly prone to a genetic background effect. Complete AZFc deletions total 3.5 Mb (mapping from ~23 to 26.8 Mb of the chromosome) and are the product of NAHR between the b2 and b4 amplicons. They account for approximately 60% of all recorded AZF deletions, occurring in one out of every ~4000 males [47, 48, 65]. The ampliconic organization of AZFc is also responsible for partial deletions that arise from NAHR between the more internal units. These partial AZFc deletions are associated to extremely variable spermatogenic disruption phenotypes (if any), leading to a debate on whether such rearrangements represent a male infertility risk or not (for selected reading: [92, 102, 103]).

**5.2. AZFc Gene Content.** As previously stated, 3 protein-coding gene families map to the AZFc interval: *BPY2*, *DAZ* and *CDY* (Figure 3). AZFc is also enriched in other transcription units, mainly for spliced but apparently non-coding transcripts of the TTTY family (*TTTY3* and *TTTY4*). Additionally, it contains an extensive array of pseudogenes. These correspond to inactive copies of AZFb and AZFc genes (*RBMY1A1*, *PRY*, *CDY* and *BPY2*), as well as AZFc-exclusive sequence families [*GOLGA2LY1* (golgi autoantigen, golgin

subfamily a, 2-like, Y-linked 1) and *CSPG4LYP1* (chondroitin sulfate proteoglycan 4-like, Y-linked pseudogene 1)].

**5.2.1. *BPY2*.** The *BPY2* gene family maps to the green AZFc amplicons (one active copy per amplicon), encoding for a testis-specific highly charged protein tentatively linked to cytoskeletal regulation in spermatogenesis [64, 104]. This gene family is further expanded by a set of pseudogene sequences also mapping to the green amplicons [65]. Despite the existence of a region of homology with chromosome 8, no autosomal homologues of *BPY2* have been identified [105]. The genomic organization of the gene is quite unique since it is constituted by nine exons but only five of which are translated into amino-acids [106]. The *BPY2* protein displays a nuclear localization throughout all male germ cell developmental stages, persisting even in ejaculated sperm [107]. The exact role played by *BPY2* in spermatogenesis is unclear, with most of the available knowledge being inferred from its protein partners. Using the yeast two-hybrid assay *BPY2* has been shown to interact with ubiquitin protein ligase E3A (*UBE3A*), a widely-expressed member of the ubiquitin protein degradation system [108]. This interaction is mediated by the HECT domain of *UBE3A*. Since *UBE3A* corresponds to a testis-expressed E3 ubiquitin protein ligase (responsible for the transfer of the ubiquitin group to the targeted substrates), *BPY2* may modulate its target specificity. Additionally, the two-hybrid assays have also identified microtubule-associated protein 1S (*MAP1S*) as an interacting protein [104]. *MAP1S* is a member of the microtubule-associated proteins (MAPs) family and is involved in microtubule binding, bundling and stabilization, as well as in the crosslinking of microtubules with microfilaments [109]. Since *MAP1S* is predominantly expressed in testis, a putative role of *BPY2*/*MAP1S* in the control of the male germ cell cytoskeletal network has been proposed [104]. The functional properties of the *MAP1S* complex are regulated by changes to its heavy chain, making this molecule a suitable target for posttranslational regulation [109]. In this context, *BPY2* emerges as a very strong candidate regulator, possibly through an *UBE3A*-mediated ubiquitination event. Protein structure prediction models also suggest the existence of a DNA/RNA binding domain (a HTH-like motif) in *BPY2*, yet experimental validation is still lacking [110].

The screening for *BPY2* mutations in infertile males has thus far been inconclusive, with no identifiable exon mutations in a cohort of 106 SCOS patients [111]. Therefore, despite suggestions that a specific promoter genotype might be associated to spermatogenic defects [111], both *BPY2* function and the phenotypical consequences associated to its disruption remain to be elucidated.

**5.2.2. *CDY*.** The chromodomain protein family (*CDY*) consists of two Y-encoded genes (*CDY1* and *CDY2*) and two autosomal copies (*CDYL* in chromosome 6 and *CDYL2* in chromosome 16) [112]. These genes are involved in post-meiotic nuclear remodelling and transcriptional regulation. The Y family members map to the yellow amplicons, with

the *CDY1* copies in AZFc (amplicons *yel1* and *yel2*) and the *CDY2* copies in AZFb (*yel3* and *yel4*) [44, 65]. A fairly large number of pseudogene sequences are also scattered throughout AZFb and AZFc. As expected, the Y-linked copies have testis-specific expression whereas the autosomal units display a more general expression pattern (*CDYL* is even ubiquitously expressed) [64, 112]. *CDY1* displays two additional transcript variants (minor and short *CDY1*) with the former showing evidence of the excision of a single intron [112, 113]. The expression of these alternative transcripts correlates significantly with complete spermatogenesis in testicular samples of azoospermic men [114].

The CDY proteins are characterized by two functional motifs: an N-terminal chromatin-binding domain (the chromodomain) and a C-terminal catalytic domain (responsible for the CoA-dependent acetyltransferase activity). The chromodomain is a typical signature of proteins involved in chromatin remodelling and gene expression regulation [115]. Accordingly, *in vitro* assays have demonstrated that recombinant CDY proteins can acetylate histone H4 (and, to a lesser degree, H2A) [116]. Furthermore, it was established that mouse *Cdyl* (*mCdyl*) transcript and protein levels peak at the elongating spermatid stage, a time frame coinciding with histone H4 hyperacetylation [116]. Given the nuclear localization of the protein and the post-meiotic expression window, the CDY family is considered a nuclear remodelling factor promoting histone H4 hyperacetylation [116]. The latter, by inducing a more relaxed chromatin configuration, may serve as trigger for the histone-to-protamine transition and subsequent nuclear condensation.

The function of the CDY proteins is not restricted to histone acetylation. Studies have associated *CDYL* and its paralogues to transcriptional corepressor complexes consisting of multiple chromatin modifying proteins [117–119]. Accordingly, the primary function of *CDYL* may be that of a transcriptional co-repressor, as observed in murine models when histone deacetylases (HDACs) bind to its catalytic domain [117]. The protein acquires its role in chromatin remodelling only when HDACs are degraded (in the elongating spermatid stage) and the CoA-binding activity of *mCdyl* is activated. This fits with data obtained from protein structure analysis indicating that the *CDY* proteins do not show obvious similarities to canonical histone acetyltransferase motifs [120]. Recently, *CDY1* has also been shown to interact with lysine 9-methylated histones (H3K9me2 and H3K9me3), although the exact functional role of this interaction is unknown [121]. The analysis of such binding properties further suggests that *CDYL2*, not *CDYL*, is the ancestor of the gene family [122].

The *CDY1* and *CDY2* proteins are isoforms with an amino-acid identity of 98% and a similar expression window [112]. This contradicts previous views that *CDY2* was required at earlier spermatogenic stages [114]. On the other hand, the global identity score between the Y-linked *CDY* proteins and *CDYL* is just 63%. The accelerated protein evolution rate of the Y-borne *CDY* sequences seems to suggest that these copies have evolved under positive selection for germline specific functions [123]. Nevertheless, identity levels are slightly higher when comparing just the

functional domains of the Y-derived and autosomal copies. In this regard, functional complementation between *CDY* genes may rescue, to some extent, the loss of the AZFb and/or AZFc variants. Fittingly, complete AZFc deletions do not alter H4 hyperacetylation levels in developing spermatids when compared to those recorded in nondeleted hypospermatogenic men [124].

5.2.3. *DAZ*. The members of the *DAZ* gene family are RNA binding proteins that play prominent roles in the establishment and maintenance of the male germ line (for selected reviews: [125, 126]). This gene family consists of three different genetic determinants: *BOLL* (*bol*, boule-like), *DAZL* and *DAZ* [127]. Of these, *DAZ* maps to AZFc (consequently being organized as a multi-copy gene family) with the remaining two being single-copy autosomal genes. Since the *DAZ* gene family contains the Y-borne *DAZ* copies, for the sake of disambiguation the italicized reference (*DAZ* genes) will refer solely to the Y determinants. The *DAZ* genes are present in one copy per red AZFc amplicon, for a total of four in the reference AZFc sequence (*DAZ1* to *DAZ4*) [65, 128]. The particularities of the palindromic organization of the reference sequence results in the clustering of the *DAZ* copies to two red amplicon duplets, with the more proximal cluster containing *DAZ1* and *DAZ2*, and the more distal cluster *DAZ3* and *DAZ4*. Nevertheless, variations in gene number have been recorded among different Y chromosomes [129, 130]. The *DAZ* genes encode for four protein isoforms varying in the number of functional domains, with the most recent data suggesting that all four are expressed in human testis [131]. They are expressed in spermatogonia, with the protein displaying a cytoplasmic localization [131–134].

Historically, *DAZ* has been the focus of considerable attention both for its link to Yq microdeletion phenotypes and evolutionary origin. In fact, almost 10 years before the sequencing of the MSY, *DAZ* was considered to be the azoospermia factor [17]. This gene also corresponded to the first reported instance of an autosome to Y transposition, an observation that triggered the resurgence of the controversy on the evolutionary fate of the Y chromosome. *DAZ* was the result of the transposition of autosomal *DAZL* to Yq, with the newly acquired sequence being subjected to several bouts of intra- and intergenic amplification followed by degeneration of some of the amplified exonic units [128, 135]. In this regard, *DAZ* corresponds to the product of diverse evolutionary forces that have ensured that a RNA-binding protein could evolve in a male-specific genomic context. The fact that its reading frame emerged unscathed from all these intense rearrangements serves as testament of positive selection, in opposition to previous reports suggesting a lack of selective pressure [128, 136].

The *DAZ* family proteins are characterized by two functional domains: a N-terminal RRM and a C-terminal *DAZ* repeat. The number of these domains varies between the *DAZ* genes and may even be polymorphic in the *DAZ* copies [137]. The *DAZ* repeat consists of a unit of 24 amino-acids that is involved in protein-protein interactions [126]. While the number of *DAZ* repeat units varies in the *DAZ*

genes (8 to 24), both *BOLL*, and *DAZL* contain a single unit. Several DAZ-interacting proteins have been identified, most of them also displaying RNA-binding properties. In fact, DAZAPI (DAZ associated protein 1), PUM2 (pumilio homolog 2), DZIPI (DAZ interacting protein 1) and DZIP3 (DAZ interacting protein 3) are not only able to interact with DAZ family members but also have RNA binding activity (DZIP3 couples this function with that of an ubiquitin protein ligase) [138–142]. Additionally, DAZAP2 (DAZ interacting protein 2) although devoid of RNA binding properties is also a regulator of the spermatogenic program. An interesting property of the DAZ family is that the proteins can interact with other members in the form of homo- or heterodimers [143]. Therefore, multiple interaction patterns might modulate the functional status of the protein in a stage-dependent manner.

The RNA binding properties of the DAZ family are associated to the translational activation of developmentally regulated transcripts. Fittingly, studies in *Drosophila* have shown that *bol* (orthologue of *BOLL*) mutations diminished the protein level of a regulated gene (*twine*) but not of its mRNA [144]. These properties can be ascribed to the RRM, an RNP-type motif with a preference for poly(U) and poly(G) UTR sequences [145–148]. The DAZ family proteins have only one RRM, except the *DAZI* and *DAZ4* copies that contain 3 and 2, respectively. Several model-based studies have tried to identify target mRNAs, yet the full range of these molecules is still open for debate [145–149]. This can be illustrated by the meagre overlap of identified candidates between the different studies. It should be noted that this repertoire of mRNA targets may be more extensive in humans since murine models lack the *DAZ* genes. Indeed, *DAZ* orthologues are absent in mammals lower than Old World monkeys. Nevertheless, the currently available list of purported mRNA targets shows some very interesting associations. The majority of the identified transcripts correspond to regulators of cell cycle progression and of general RNA metabolism. Transcripts for genes involved in spermiogenesis also seem to be targeted by murine *Dazl*, consistent with *DAZL* expression during cytodifferentiation [125]. Such data, although still awaiting more extensive validation, are indicative that the DAZ family plays an important role in the orchestration of spermatogenesis. Fittingly, overexpression of *BOLL*, *DAZL* and *DAZ* promotes the formation of haploid cells in human embryonic stem cell differentiation systems [150].

The molecular mechanism through which the DAZ family exerts its control over protein expression seems to involve the enhancement of translation initiation. A model has been proposed based on the binding of the DAZ proteins to the 3' UTR of target mRNAs followed by the recruitment of poly(A)-binding proteins to the transcripts [151]. These in turn enhance the recruitment of ribosomal subunits and consequently the onset of translational activation. Accordingly, a report has associated *DAZL* to the actively translating ribosome fraction of testis extracts, although the robustness of this observation has been questioned [125, 152]. Moreover, the DAZ family is also involved in the transport and storage of transcripts [153]. This function

seems to be dependent on the dynein-dynactin complex and leads to the storage of the molecules as transcriptionally quiescent particles waiting for proper developmental cues to trigger their activation. This is particularly relevant in light of the transcriptional shutdown associated to chromatin remodelling in spermiogenesis. On a more general note, the DAZ family corresponds to an active regulator of the spermatogenic program, operating at multiple levels via mediation of transcript transport/storage, translation initiation and protein function.

Despite the significant roles in spermatogenesis attributed to the *DAZ* genes, their complete deletion is not incompatible either with sperm production (albeit at extremely low levels) or with rare instances of natural conception [47, 48, 95–97]. This can be explained in part by some functional overlap between DAZ family members. Indeed, *DAZ* and *DAZL* share 93% similarity in the RRM region and 80–90% in the DAZ repeat domain [125]. In this context, the loss of the Y-borne *DAZ* copies may be compensated by *DAZL*. This functional overlap is illustrated by the fact that a human *DAZ* transgene can partially rescue the spermatogenic impairment phenotype of *Dazl*-null mice [154, 155]. Nevertheless, despite an increase in the germ cell population and meiotic progression up to the pachytene stage, the rescue phenotype is insufficient to ensure mature sperm production. It should be noted that not even a *DAZL* transgene was able to extend the rescue effect to post-meiotic stages [155], a clear indicator that interspecies differences played a decisive role in determining the degree of rescue.

In summary, AZFc genes play important roles for male fertility. The majority of published studies focus on the functional properties of *CDY* and *DAZ*. Such reports indicate that both genes may be the main functional determinants of the interval. Yet, the effects of their deletion can presumably be minimized by some degree of phenotypical rescue ensured by the autosomal homologues. This might account for the less severe spermatogenic impairment phenotype associated to AZFc deletions when compared to those removing AZFa or AZFb. Evidence for functionally related copies being able to partially rescue deletion phenotypes is available in other genomic contexts. Specifically, the dynamics of the *SMN1* and *SMN2* genes (survival of motor neuron 1 and 2, respectively) in the context of spinal muscular atrophy is a prime example [156]. Nevertheless, the still largely uncharacterized properties of *BPY2* advise some caution on relegating this gene to a secondary role in spermatogenesis. An additional consideration regards the possibility of the different copies inside each AZFc gene family varying slightly in function. In this scenario, each copy would contribute differently to the overall function of the gene family, with the effects of some determinants being more decisive than others. To test this hypothesis, several authors have suggested the study of evolutionary branches of the Y chromosome where partial AZFc deletions have become fixed without any apparent consequences for male fertility [37, 157]. Although such authors argue that the copies remaining in these chromosomes represent the key determinants of the AZFc gene families, advances have thus far been inconclusive. Regardless of such considerations, the

variable levels of spermatogenic impairment observed in AZFc deletions are a clear indicator that this region is prone to a more pronounced phenotypical modulation than the other two AZF intervals. In this regard, factors such as genetic background and other epigenetic/environmental cues may play a crucial role in defining the deletion's outcome.

Since the complete AZFc deletion removes a still significant Yq stretch, a deleterious effect on cell cycle progression arising from pairing deficiencies may be considered. Fittingly, an association between AZFc deletions and minor impairment of telomere clustering has been reported [91]. AZFc deletions have equally been linked to instances of prolonged zygotene stage and reduced XY condensation [158]. However, since the level of these disturbances is small, their effective impact on spermatogenesis is highly speculative.

## 6. Final Considerations and Future Perspectives

Despite the tremendous breakthroughs recorded in the past few years, our knowledge of AZF gene function is still considerably limited. The reasons for this can be ascribed to both technical issues and to the inherent complexity of this biological system. In technical terms, the lack of easily accessible animal models (AZF sequence architectures are only present in some primate lineages) and of *in vitro* spermatogenic cell lines introduce clear restrictions to a faster development of the field. Additionally, the biological properties of the AZF regions further complicate matters, as attested by the tremendous variability associated to the AZFb and AZFc sequences, as well as the intricate regulation of the corresponding genetic determinants. Clearly, the future research lines to be pursued in this field consist of the full sequencing of AZF diversity across the Y chromosome population and of a more in-depth functional characterization of AZF genes. Both represent considerable challenges that will ultimately yield benefits for a significant fraction of infertile couples. Although it is still too premature to envisage AZF gene therapy approaches, the identification of novel AZF molecular disturbances and their associated phenotypes is of clear importance for the clinical management of these patients.

Based on the state-of-the-art discussed in this paper, the AZF genes display considerable differences in their genomic organization and molecular role. The available evidence indicates that *DDX3Y* in AZFa, *KDM5D* and *RBMY1A1* in AZFb, and *DAZ* and *CDY* in AZFb/c represent key determinants for spermatogenesis. Yet, the characterization of the remaining AZF genes is still quite incipient. Thus, advances in this area are of paramount importance for a more comprehensive outlook on the reproductive fitness of the Y chromosome. Appropriately, the screening of infertile males for specific deletions or other (epi)genetic alterations in AZF may reveal new clinically-relevant mutations. Coupling such knowledge with functional data on the affected biological processes would translate into significant conceptual advances in male reproductive genetics.

## Abbreviation List

AZF:	Azoospermia factor
HDAC:	Histone deacetylase
HERV:	Human endogenous retrovirus
IR:	Inverted repeat
MAP:	Microtubule-associated protein
MSY:	Male specific region of the Y chromosome
NAHR:	Non-allelic homologous recombination
PGC:	Primordial germ cell
RRM:	RNA recognition motif
SCOS:	Sertoli cell-only syndrome
STS:	Sequence-tagged site
UTR:	Untranslated region
X:	X chromosome
Y:	Y chromosome
Yq:	Long arm of the Y chromosome

## Acknowledgments

This work was partially funded by CIGMH (Centro de Investigação em Genética Molecular Humana). P. Navarro-Costa was supported by a Ph.D. fellowship from Fundação para a Ciência e a Tecnologia (no. SFRH/BD/16662/2004). All authors declare that they have no competing interests.

## References

- [1] L. Tiepolo and O. Zuffardi, "Localization of factors controlling spermatogenesis in the nonfluorescent portion of the human Y chromosome long arm," *Human Genetics*, vol. 34, no. 2, pp. 119–124, 1976.
- [2] A. C. Chandley and P. Edmond, "Meiotic studies on a subfertile patient with a ring Y chromosome," *Cytogenetics*, vol. 10, no. 4, pp. 295–304, 1971.
- [3] J. German, J. L. Simpson, and G. A. McLemore Jr., "Abnormalities of human sex chromosomes. I. A ring Y without mosaicism," *Annales de Genetique*, vol. 16, no. 4, pp. 225–231, 1973.
- [4] R. L. Neu, M. J. Barlow Jr., and L. I. Gardner, "A 46,XYq- male with aspermia," *Fertility and Sterility*, vol. 24, no. 10, pp. 811–813, 1973.
- [5] N. A. Affara, L. Florentin, N. Morrison et al., "Regional assignment of Y-linked DNA probes by deletion mapping and their homology with X-chromosome and autosomal sequences," *Nucleic acids research*, vol. 14, no. 13, pp. 5353–5373, 1986.
- [6] G. Vergnaud, D. C. Page, and M.-C. Simmler, "A deletion map of the human Y chromosome based on DNA hybridization," *American Journal of Human Genetics*, vol. 38, no. 2, pp. 109–124, 1986.
- [7] B. Bardoni, O. Zuffardi, S. Guioli et al., "A deletion map of the human Yq11 region: implications for the evolution of the Y chromosome and tentative mapping of a locus involved in spermatogenesis," *Genomics*, vol. 11, no. 2, pp. 443–451, 1991.
- [8] K. Ma, A. Sharkey, S. Kirsch et al., "Towards the molecular localisation of the AZF locus: mapping of microdeletions in azoospermic men within 14 subintervals of interval 6 of the human Y chromosome," *Human Molecular Genetics*, vol. 1, no. 1, pp. 29–33, 1992.





- [9] P. Vogt, A. C. Chandley, T. B. Hargreave, R. Keil, K. Ma, and A. Sharkey, "Microdeletions in interval 6 of the Y chromosome of males with idiopathic sterility point to disruption of AZF, a human spermatogenesis gene," *Human Genetics*, vol. 89, no. 5, pp. 491–496, 1992.
- [10] S. Foote, D. Vollrath, A. Hilton, and D. C. Page, "The human Y chromosome: overlapping DNA clones spanning the euchromatic region," *Science*, vol. 258, no. 5079, pp. 60–66, 1992.
- [11] D. Vollrath, S. Foote, A. Hilton et al., "The human Y chromosome: a 43-interval map based on naturally occurring deletions," *Science*, vol. 258, no. 5079, pp. 52–59, 1992.
- [12] S. Kirsch, R. Keil, A. Edelmann et al., "Molecular analysis of the genomic structure of the human Y chromosome in the euchromatic part of its long arm (Yq11)," *Cytogenetics and Cell Genetics*, vol. 75, no. 2-3, pp. 197–206, 1996.
- [13] K. Ma, J. D. Inglis, A. Sharkey et al., "A Y chromosome gene family with RNA-binding protein homology: candidates for the azoospermia factor AZF controlling human spermatogenesis," *Cell*, vol. 75, no. 7, pp. 1287–1295, 1993.
- [14] S. Nagafuchi, M. Namiki, Y. Nakahori, N. Kondoh, A. Okuyama, and Y. Nakagome, "A minute deletion of the Y chromosome in men with azoospermia," *Journal of Urology*, vol. 150, no. 4, pp. 1155–1157, 1993.
- [15] K. Kobayashi, K. Mizuno, A. Hida et al., "PCR analysis of the Y chromosome long arm in azoospermic patients: evidence for a second locus required for spermatogenesis," *Human Molecular Genetics*, vol. 3, no. 11, pp. 1965–1967, 1994.
- [16] P. H. Vogt, A. Edelmann, S. Kirsch et al., "Human Y chromosome azoospermia factors (AZF) mapped to different subregions in Yq11," *Human Molecular Genetics*, vol. 5, pp. 933–943, 1996.
- [17] R. Reijo, T. -Y. Lee, P. Salo et al., "Diverse spermatogenic defects in humans caused by Y chromosome deletions encompassing a novel RNA-binding protein gene," *Nature Genetics*, vol. 10, no. 4, pp. 383–393, 1995.
- [18] J. L. Pryor, M. Kent-First, A. Muallem et al., "Microdeletions in the Y chromosome of infertile men," *New England Journal of Medicine*, vol. 336, no. 8, pp. 534–539, 1997.
- [19] M. Simoni, E. Bakker, and C. Krausz, "EAA/EMQN best practice guidelines for molecular diagnosis of y-chromosomal microdeletions. State of the art 2004," *International Journal of Andrology*, vol. 27, no. 4, pp. 240–249, 2004.
- [20] H. Skaletsky, T. Kuroda-Kawaguchi, P. J. Minx et al., "The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes," *Nature*, vol. 423, no. 6942, pp. 825–837, 2003.
- [21] C. Sun, H. Skaletsky, B. Birren et al., "An azoospermic man with a de novo point mutation in the Y-chromosomal gene USP9Y," *Nature Genetics*, vol. 23, no. 4, pp. 429–432, 1999.
- [22] P. Blanco, M. Shlumukova, C. A. Sargent, M. A. Jobling, N. Affara, and M. E. Hurler, "Divergent outcomes of intrachromosomal recombination on the human Y chromosome: male infertility and recurrent polymorphism," *Journal of Medical Genetics*, vol. 37, no. 10, pp. 752–758, 2000.
- [23] C. Kamp, P. Hirschmann, H. Voss, K. Huellen, and P. H. Vogt, "Two long homologous retroviral sequence blocks in proximal Yq11 cause AZFa microdeletions as a result of intrachromosomal recombination events," *Human Molecular Genetics*, vol. 9, no. 17, pp. 2563–2572, 2000.
- [24] C. Sun, H. Skaletsky, S. Rozen et al., "Deletion of azoospermia factor a (AZFa) region of human Y chromosome caused by recombination between HERV15 proviruses," *Human Molecular Genetics*, vol. 9, no. 15, pp. 2291–2296, 2000.
- [25] C. Kamp, K. Huellen, S. Fernandes et al., "High deletion frequency of the complete AZFa sequence in men with Sertoli-cell-only syndrome," *Molecular Human Reproduction*, vol. 7, no. 10, pp. 987–994, 2001.
- [26] C. Krausz and S. Degl'Innocenti, "Y chromosome and male infertility: update, 2006," *Frontiers in Bioscience*, vol. 11, no. 3, pp. 3049–3061, 2006.
- [27] E. Bosch and M. A. Jobling, "Duplications of the AZFa region of the human Y chromosome are mediated by homologous recombination between HERVs and are compatible with male fertility," *Human Molecular Genetics*, vol. 12, no. 3, pp. 341–347, 2003.
- [28] W. M. Baarends, R. van der Laan, and J. A. Grootegoed, "Specific aspects of the ubiquitin system in spermatogenesis," *Journal of Endocrinological Investigation*, vol. 23, no. 9, pp. 597–604, 2000.
- [29] K. H. Lee, G. J. Song, I. S. Kang et al., "Ubiquitin-specific protease activity of USP9Y, a male infertility gene on the Y chromosome," *Reproduction, Fertility and Development*, vol. 15, no. 1-2, pp. 129–133, 2003.
- [30] G. M. Brown, R. A. Furlong, C. A. Sargent et al., "Characterisation of the coding sequence and fine mapping of the human DFFRY gene and comparative expression analysis and mapping to the Sxrb interval of the mouse Y chromosome of the Dffry gene," *Human Molecular Genetics*, vol. 7, no. 1, pp. 97–107, 1998.
- [31] N. M. Hall, G. M. Brown, R. A. Furlong et al., "Usp9y (ubiquitin-specific protease 9 gene on the Y) is associated with a functional promoter and encodes an intact open reading frame homologous to Usp9x that is under selective constraint," *Mammalian Genome*, vol. 14, no. 7, pp. 437–447, 2003.
- [32] P. H. Vogt, C. L. Falcao, R. Hanstein, and J. Zimmer, "The AZF proteins," *International Journal of Andrology*, vol. 31, no. 4, pp. 383–394, 2008.
- [33] T. Noma, Y. Kanai, M. Kanai-Azuma et al., "Stage- and sex-dependent expressions of Usp9x, an X-linked mouse ortholog of Drosophila Fat facets, during gonadal development and oogenesis in mice," *Mechanisms of Development*, vol. 119, no. 1, pp. S91–S95, 2002.
- [34] C. Krausz, S. Degl'Innocenti, F. Nuti et al., "Natural transmission of USP9Y gene mutations: a new perspective on the role of AZFa genes in male fertility," *Human Molecular Genetics*, vol. 15, no. 18, pp. 2673–2681, 2006.
- [35] A. Luddi, M. Margollicci, L. Gambera et al., "Spermatogenesis in a man with complete deletion of USP9Y," *New England Journal of Medicine*, vol. 360, no. 9, pp. 881–885, 2009.
- [36] G. H. Perry, R. Y. Tito, and B. C. Verrelli, "The evolutionary history of human and chimpanzee Y-chromosome gene loss," *Molecular Biology and Evolution*, vol. 24, no. 3, pp. 853–859, 2007.
- [37] C. Tyler-Smith, "An evolutionary perspective on Y-chromosomal variation and male infertility," *International Journal of Andrology*, vol. 31, no. 4, pp. 376–382, 2008.
- [38] C. Tyler-Smith and C. Krausz, "The Will-o'-the-wisp of genetics—hunting for the azoospermia factor gene," *New England Journal of Medicine*, vol. 360, no. 9, pp. 925–927, 2009.
- [39] A. Rosner and B. Rinkevich, "The DDX3 subfamily of the DEAD box helicases: divergent roles as unveiled by studying different organisms and in vitro assays," *Current Medicinal Chemistry*, vol. 14, no. 23, pp. 2517–2525, 2007.
- [40] H. J. Ditton, J. Zimmer, C. Kamp, E. Rajpert-De Meyts, and P. H. Vogt, "The AZFa gene DBY (DDX3Y) is widely

- transcribed but the protein is limited to the male germ cells by translation control,” *Human Molecular Genetics*, vol. 13, no. 19, pp. 2333–2341, 2004.
- [41] T. Sekiguchi, H. Iida, J. Fukumura, and T. Nishimoto, “Human DDX3Y, the Y-encoded isoform of RNA helicase DDX3, rescues a hamster temperature-sensitive ET24 mutant cell line with a DDX3X mutation,” *Experimental Cell Research*, vol. 300, no. 1, pp. 213–222, 2004.
- [42] C. Foresta, A. Ferlin, and E. Moro, “Deletion and expression analysis of AZFa genes on the human Y chromosome revealed a major role for DBY in male infertility,” *Human Molecular Genetics*, vol. 9, no. 8, pp. 1161–1169, 2000.
- [43] S. Repping, H. Skaletsky, J. Lange et al., “Recombination between palindromes P5 and P1 on the human Y chromosome causes massive deletions and spermatogenic failure,” *American Journal of Human Genetics*, vol. 71, no. 4, pp. 906–922, 2002.
- [44] A. Ferlin, E. Moro, A. Rossi, B. Dallapiccola, and C. Foresta, “The human Y chromosome’s azoospermia factor b (AZFb) region: sequence, structure, and deletion analysis in infertile men,” *Journal of Medical Genetics*, vol. 40, no. 1, pp. 18–24, 2003.
- [45] Y. Yang, M. Y. Ma, C. Y. Xiao, L. Li, S. W. Li, and S. Z. Zhang, “Massive deletion in AZFb/b+c and azoospermia with Sertoli cell only and/or maturation arrest,” *International Journal of Andrology*, vol. 31, no. 6, pp. 573–578, 2008.
- [46] P. Costa, R. Gonçalves, C. Ferrás et al., “Identification of new breakpoints in AZFb and AZFc,” *Molecular Human Reproduction*, vol. 14, no. 4, pp. 251–258, 2008.
- [47] A. Ferlin, B. Arredi, E. Speltra et al., “Molecular and clinical characterization of Y chromosome microdeletions in infertile men: a 10-year experience in Italy,” *Journal of Clinical Endocrinology and Metabolism*, vol. 92, no. 3, pp. 762–770, 2007.
- [48] M. Simoni, F. Tüttelmann, J. Gromoll, and E. Nieschlag, “Clinical consequences of microdeletions of the Y chromosome: the extended Münster experience,” *Reproductive BioMedicine Online*, vol. 16, no. 2, pp. 289–303, 2008.
- [49] C. Patrat, T. Bienvenu, L. Janny et al., “Clinical data and parenthood of 63 infertile and Y-microdeleted men,” *Fertility and Sterility*, 2008.
- [50] V. W. C. Yu, C. Gauthier, and R. St-Arnaud, “Inhibition of ATF4 transcriptional activity by FIAT/ $\gamma$ -taxilin modulates bone mass accrual,” *Annals of the New York Academy of Sciences*, vol. 1068, no. 1, pp. 131–142, 2006.
- [51] A. W. Bergen, M. Pratt, P. T. Mehlman, and D. Goldman, “Evolution of RPS4Y,” *Molecular Biology and Evolution*, vol. 15, no. 11, pp. 1412–1419, 1998.
- [52] O. Andrés, T. Kellermann, F. López-Giráldez, J. Rozas, X. Domingo-Roura, and M. Bosch, “RPS4Y gene family evolution in primates,” *BMC Evolutionary Biology*, vol. 8, no. 1, article 142, 2008.
- [53] A. Roll-Mecak, B.-S. Shin, T. E. Dever, and S. K. Burley, “Engaging the ribosome: universal IFs of translation,” *Trends in Biochemical Sciences*, vol. 26, no. 12, pp. 705–709, 2001.
- [54] S. F. Mitchell and J. R. Lorsch, “Should I stay or should I go? Eukaryotic translation initiation factors 1 and 1A control start codon recognition,” *Journal of Biological Chemistry*, vol. 283, no. 41, pp. 27345–27349, 2008.
- [55] M. G. Lee, J. Norman, A. Shilatfard, and R. Shiekhattar, “Physical and functional association of a trimethyl H3K4 demethylase and Ring6a/MBLR, a polycomb-like protein,” *Cell*, vol. 128, no. 5, pp. 877–887, 2007.
- [56] C. Akimoto, H. Kitagawa, T. Matsumoto, and S. Kato, “Spermatogenesis-specific association of SMCY and MSH5,” *Genes to Cells*, vol. 13, no. 6, pp. 623–633, 2008.
- [57] C. Santos, L. Rodriguez-Revilla, I. Madrigal, C. Badenas, M. Pineda, and M. Milá, “A novel mutation in JARID1C gene associated with mental retardation,” *European Journal of Human Genetics*, vol. 14, no. 5, pp. 583–586, 2006.
- [58] S. Iwase, F. Lan, P. Bayliss et al., “The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases,” *Cell*, vol. 128, no. 6, pp. 1077–1088, 2007.
- [59] M. Tahiliani, P. Mei, R. Fang et al., “The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation,” *Nature*, vol. 447, no. 7144, pp. 601–605, 2007.
- [60] F. E. Abidi, L. Holloway, C. A. Moore et al., “Mutations in JARID1C are associated with X-linked mental retardation, short stature and hyperreflexia,” *Journal of Medical Genetics*, vol. 45, no. 12, pp. 787–793, 2008.
- [61] M. Ho, J. Chelly, N. Carter, A. Danek, P. Cracker, and A. P. Monaco, “Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein,” *Cell*, vol. 77, no. 6, pp. 869–880, 1994.
- [62] H. H. Jung, A. Danek, and B. M. Frey, “McLeod syndrome: a neurohaematological disorder,” *Vox Sanguinis*, vol. 93, no. 2, pp. 112–121, 2007.
- [63] J. Peng, C. M. Redman, X. Wu et al., “Insights into extensive deletions around the XK locus associated with McLeod phenotype and characterization of two novel cases,” *Gene*, vol. 392, no. 1–2, pp. 142–150, 2007.
- [64] B. T. Lahn and D. C. Page, “Functional coherence of the human Y chromosome,” *Science*, vol. 278, no. 5338, pp. 675–680, 1997.
- [65] T. Kuroda-Kawaguchi, H. Skaletsky, L. G. Brown et al., “The AZFc region of the Y chromosome features massive palindromes and uniform recurrent deletions in infertile men,” *Nature Genetics*, vol. 29, no. 3, pp. 279–286, 2001.
- [66] A. Tessari, E. Salata, A. Ferlin, L. Bartoloni, M. L. Slongo, and C. Foresta, “Characterization of HSFY, a novel AZFb gene on the Y chromosome with a possible role in human spermatogenesis,” *Molecular Human Reproduction*, vol. 10, no. 4, pp. 253–258, 2004.
- [67] T. Shinka, Y. Sato, G. Chen et al., “Molecular characterization of heat shock-like factor encoded on the human Y chromosome, and implications for male infertility,” *Biology of Reproduction*, vol. 71, no. 1, pp. 297–306, 2004.
- [68] K. Kinoshita, T. Shinka, Y. Sato et al., “Expression analysis of a mouse orthologue of HSFY, a candidate for the azoospermic factor on the human Y chromosome,” *Journal of Medical Investigation*, vol. 53, no. 1–2, pp. 117–122, 2006.
- [69] G. Vinci, F. Raicu, L. Popa, O. Popa, R. Cocos, and K. McElreavey, “A deletion of a novel heat shock gene on the Y chromosome associated with azoospermia,” *Molecular Human Reproduction*, vol. 11, no. 4, pp. 295–298, 2005.
- [70] Y. Sato, K. Yoshida, T. Shinka, S. Nozawa, Y. Nakahori, and T. Iwamoto, “Altered expression pattern of heat shock transcription factor, Y chromosome (HSFY) may be related to altered differentiation of spermatogenic cells in testes with deteriorated spermatogenesis,” *Fertility and Sterility*, vol. 86, no. 3, pp. 612–618, 2006.
- [71] M. Dromard, G. Bompard, M. Glondu-Lassis, C. Puech, D. Chalbos, and G. Freiss, “The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor

- substrate-1 dephosphorylation," *Cancer Research*, vol. 67, no. 14, pp. 6806–6813, 2007.
- [72] K. Stouffs, W. Lissens, L. Van Landuyt, H. Tournaye, A. Van Steirteghem, and I. Liebaers, "Characterization of the genomic organization, localization and expression of four PRY genes (PRY1, PRY2, PRY3 and PRY4)," *Molecular Human Reproduction*, vol. 7, no. 7, pp. 603–610, 2001.
- [73] K. Stouffs, W. Lissens, G. Verheyen et al., "Expression pattern of the Y-linked PRY gene suggests a function in apoptosis but not in spermatogenesis," *Molecular Human Reproduction*, vol. 10, no. 1, pp. 15–21, 2004.
- [74] N.-N. Chai, H. Zhou, J. Hernandez, H. Najmabadi, S. Bhasin, and P. H. Yen, "Structure and organization of the RBMY genes on the human Y chromosome: transposition and amplification of an ancestral autosomal hnRNPG gene," *Genomics*, vol. 49, no. 2, pp. 283–289, 1998.
- [75] D. J. Elliott, M. R. Millar, K. Oghene et al., "Expression of RBM in the nuclei of human germ cells is dependent on a critical region of the Y chromosome long arm," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 8, pp. 3848–3853, 1997.
- [76] W. Schempp, A. Binkele, J. Arnemann et al., "Comparative mapping of YRRM- and TSPY-related cosmids in man and hominoid apes," *Chromosome Research*, vol. 3, no. 4, pp. 227–234, 1995.
- [77] H. Najmabadi, N. Chai, A. Kapali et al., "Genomic structure of a Y-specific ribonucleic acid binding motif-containing gene: a putative candidate for a subset of male infertility," *Journal of Clinical Endocrinology and Metabolism*, vol. 81, no. 6, pp. 2159–2164, 1996.
- [78] D. J. Elliott, "The role of potential splicing factors including RBMY, RBMX, hnRNPG-T and STAR proteins in spermatogenesis," *International Journal of Andrology*, vol. 27, no. 6, pp. 328–334, 2004.
- [79] Y. Shamoo, N. Abdul-Manan, and K. R. Williams, "Multiple RNA binding domains (RBDs) just don't add up," *Nucleic Acids Research*, vol. 23, no. 5, pp. 725–728, 1995.
- [80] N. B. Hecht, "Molecular mechanisms of male germ cell differentiation," *BioEssays*, vol. 20, no. 7, pp. 555–561, 1998.
- [81] D. J. Elliott, K. Oghene, G. Makarov et al., "Dynamic changes in the subnuclear organisation of pre-mRNA splicing proteins and RBM during human germ cell development," *Journal of Cell Science*, vol. 111, no. 9, pp. 1255–1265, 1998.
- [82] D. J. Elliott, C. F. Bourgeois, A. Klink, J. Stévenin, and H. J. Cooke, "A mammalian germ cell-specific RNA-binding protein interacts with ubiquitously expressed proteins involved in splice site selection," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 11, pp. 5717–5722, 2000.
- [83] J. P. Venables, D. J. Elliott, O. V. Makarova, E. M. Makarov, H. J. Cooke, and I. C. Eperon, "RBMY, a probable human spermatogenesis factor, and other hnRNP G proteins interact with Tra2 $\beta$  and affect splicing," *Human Molecular Genetics*, vol. 9, no. 5, pp. 685–694, 2000.
- [84] D. Longman, I. L. Johnstone, and J. F. Cáceres, "Functional characterization of SR and SR-related genes in *Caenorhabditis elegans*," *EMBO Journal*, vol. 19, no. 7, pp. 1625–1637, 2000.
- [85] J. P. Venables, C. Vernet, S. L. Chew et al., "T-STAR/ETOILE: a novel relative of SAM68 that interacts with an RNA-binding protein implicated in spermatogenesis," *Human Molecular Genetics*, vol. 8, no. 6, pp. 959–969, 1999.
- [86] D. J. Elliott, J. P. Venables, C. S. Newton et al., "An evolutionarily conserved germ cell-specific hnRNP is encoded by a retrotransposed gene," *Human Molecular Genetics*, vol. 9, no. 14, pp. 2117–2124, 2000.
- [87] I. Ehrmann, C. Dalglish, A. Tsaousi et al., "Haploinsufficiency of the germ cell-specific nuclear RNA binding protein hnRNP G-T prevents functional spermatogenesis in the mouse," *Human Molecular Genetics*, vol. 17, no. 18, pp. 2803–2818, 2008.
- [88] L. Skrisovska, C. F. Bourgeois, R. Stefl et al., "The testis-specific human protein RBMY recognizes RNA through a novel mode of interaction," *EMBO Reports*, vol. 8, no. 4, pp. 372–379, 2007.
- [89] M. Zeng, H. Sun, S. Chen et al., "Identification of target messenger RNA substrates for mouse RBMY," *Molecular Human Reproduction*, vol. 14, no. 6, pp. 331–336, 2008.
- [90] N. N. Chai, E. C. Salido, and P. H. Yen, "Multiple functional copies of the RBM gene family, a spermatogenesis candidate on the human Y chromosome," *Genomics*, vol. 45, no. 2, pp. 355–361, 1997.
- [91] L. Yogev, S. Segal, E. Zeharia et al., "Sex chromosome alignment at meiosis of azoospermic men with azoospermia factor microdeletion," *Journal of Andrology*, vol. 25, no. 1, pp. 110–116, 2004.
- [92] P. Navarro-Costa, J. Goncalves, and C. E. Plancha, "The AZFc region of the Y chromosome: at the crossroads between genetic diversity and male infertility," *Human Reproduction Update*. In press.
- [93] Y.-H. Yu, Y.-W. Lin, J.-F. Yu, W. Schempp, and P. H. Yen, "Evolution of the DAZ gene and the AZFc region on primate Y chromosomes," *BMC Evolutionary Biology*, vol. 8, no. 1, article 96, 2008.
- [94] S. Repping, S. K. M. Van Daalen, L. G. Brown et al., "High mutation rates have driven extensive structural polymorphism among human Y chromosomes," *Nature Genetics*, vol. 38, no. 4, pp. 463–467, 2006.
- [95] B. Kühnert, J. Gromoll, E. Kostova et al., "Case report: natural transmission of an AZFc Y-chromosomal microdeletion from father to his sons," *Human Reproduction*, vol. 19, no. 4, pp. 886–888, 2004.
- [96] X. Y. Xia, Y. X. Cui, L. J. Pan et al., "Analysis of an AZFc deletion family with natural transmission," *Zhonghua Nan Ke Xue*, vol. 12, no. 8, pp. 720–722, 2006.
- [97] A. E. Calogero, M. R. Garofalo, N. Barone et al., "Spontaneous transmission from a father to his son of a Y chromosome microdeletion involving the deleted in azoospermia (DAZ) gene," *Journal of Endocrinological Investigation*, vol. 25, no. 7, pp. 631–634, 2002.
- [98] P. L. Chang, M. V. Sauer, and S. Brown, "Y chromosome microdeletion in a father and his four infertile sons," *Human Reproduction*, vol. 14, no. 11, pp. 2689–2694, 1999.
- [99] V. Gatta, L. Stuppia, G. Calabrese, E. Morizio, P. Guanciali-Franchi, and G. Palka, "A new case of Yq microdeletion transmitted from a normal father to two infertile sons," *Journal of Medical Genetics*, vol. 39, no. 6, p. E27, 2002.
- [100] N. Saut, P. Terriou, A. Navarro, N. Lévy, and M. J. Mitchell, "The human Y chromosome genes BPY2, CDY1 and DAZ are not essential for sustained fertility," *Molecular Human Reproduction*, vol. 6, no. 9, pp. 789–793, 2000.
- [101] D. S. Cram, K. Ma, S. Bhasin et al., "Y chromosome analysis of infertile men and their sons conceived through intracytoplasmic sperm injection: vertical transmission of deletions and rarity of de novo deletions," *Fertility and Sterility*, vol. 74, no. 5, pp. 909–915, 2000.

- [102] P. Navarro-Costa, L. Pereira, C. Alves et al., "Characterizing partial AZFc deletions of the Y chromosome with amplicon-specific sequence markers," *BMC Genomics*, vol. 8, article 342, 2007.
- [103] C. Giachini, I. Laface, E. Guarducci, G. Balercia, G. Forti, and C. Krausz, "Partial AZFc deletions and duplications: clinical correlates in the Italian population," *Human Genetics*, vol. 124, no. 4, pp. 399–410, 2008.
- [104] E. Y. M. Wong, J. Y. M. Tse, K.-M. Yao, V. C. H. Lui, P.-C. Tam, and W. S. B. Yeung, "Identification and characterization of human VCY2-interacting protein: VCY2IP-1, a microtubule-associated protein-like protein," *Biology of Reproduction*, vol. 70, no. 3, pp. 775–784, 2004.
- [105] L. Stuppia, V. Gatta, O. Scariolla et al., "Identification in chromosome 8q11 of a region of homology with the g1 amplicon of the Y chromosome and functional analysis of the BEYLA gene," *Genomics*, vol. 85, no. 2, pp. 280–283, 2005.
- [106] L. Stuppia, V. Gatta, I. Fogh et al., "Genomic organization, physical mapping, and involvement in Yq microdeletions of the VCY2 (BPY 2) gene," *Genomics*, vol. 72, no. 2, pp. 153–157, 2001.
- [107] J. Y. M. Tse, E. Y. M. Wong, A. N. Y. Cheung, W. S. O. P. C. Tam, and W. S. B. Yeung, "Specific expression of VCY2 in human male germ cells and its involvement in the pathogenesis of male infertility," *Biology of Reproduction*, vol. 69, no. 3, pp. 746–751, 2003.
- [108] E. Y. M. Wong, J. Y. M. Tse, K.-M. Yao, P.-C. Tam, and W. S. B. Yeung, "VCY2 protein interacts with the HECT domain of ubiquitin-protein ligase E3A," *Biochemical and Biophysical Research Communications*, vol. 296, no. 5, pp. 1104–1111, 2002.
- [109] Z. Orbán-Németh, H. Simader, S. Badurek, A. Trančíková, and F. Propst, "Microtubule-associated protein 1S, a short and ubiquitously expressed member of the microtubule-associated protein 1 family," *Journal of Biological Chemistry*, vol. 280, no. 3, pp. 2257–2265, 2005.
- [110] K. Ginalski, L. Rychlewski, D. Baker, and N. V. Grishin, "Protein structure prediction for the male-specific region of the human Y chromosome," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 8, pp. 2305–2310, 2004.
- [111] J. Choi, E. Koh, H. Suzuki, Y. Maeda, A. Yoshida, and M. Namiki, "Alu sequence variants of the BPY2 gene in proven fertile and infertile men with Sertoli cell-only phenotype," *International Journal of Urology*, vol. 14, no. 5, pp. 431–435, 2007.
- [112] B. T. Lahn and D. C. Page, "Retroposition of autosomal mRNA yielded testis-specific gene family on human Y chromosome," *Nature Genetics*, vol. 21, no. 4, pp. 429–433, 1999.
- [113] S. E. Kleiman, A. Lagziel, L. Yogev, A. Botchan, G. Paz, and H. Yavetz, "Expression of CDY1 may identify complete spermatogenesis," *Fertility and Sterility*, vol. 75, no. 1, pp. 166–173, 2001.
- [114] S. E. Kleinman, L. Yogev, R. Hauser et al., "Members of the CDY family have different expression patterns: CDY1 transcripts have the best correlation with complete spermatogenesis," *Human Genetics*, vol. 113, no. 6, pp. 486–492, 2003.
- [115] K. Tajul-Arifin, R. Teasdale, T. Ravasi et al., "Identification and analysis of chromodomain-containing proteins encoded in the mouse transcriptome," *Genome Research*, vol. 13, no. 6B, pp. 1416–1429, 2003.
- [116] B. T. Lahn, Z. L. Tang, J. Zhou et al., "Previously uncharacterized histone acetyltransferases implicated in mammalian spermatogenesis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 13, pp. 8707–8712, 2002.
- [117] C. Caron, C. Pivot-Pajot, L. A. van Grunsven et al., "Cdy1: a new transcriptional co-repressor," *EMBO Reports*, vol. 4, no. 9, pp. 877–882, 2003.
- [118] Y. Shi, J.-I. Sawada, G. Sui et al., "Coordinated histone modifications mediated by a CtBP co-repressor complex," *Nature*, vol. 422, no. 6933, pp. 735–738, 2003.
- [119] P. Mulligan, T. F. Westbrook, M. Ottinger et al., "CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation," *Molecular Cell*, vol. 32, no. 5, pp. 718–726, 2008.
- [120] H. Wu, J. Min, T. Antoshenko, and A. N. Plotnikov, "Crystal structures of human CDY proteins reveal a crotonase-like fold," *Proteins: Structure, Function and Bioinformatics*, vol. 76, no. 4, pp. 1054–1061, 2009.
- [121] J. Kim, J. Daniel, A. Espejo et al., "Tudor, MBT and chromo domains gauge the degree of lysine methylation," *EMBO Reports*, vol. 7, no. 4, pp. 397–403, 2006.
- [122] W. Fischle, H. Franz, S. A. Jacobs, C. D. Allis, and S. Khorasanizadeh, "Specificity of the chromodomain Y chromosome family of chromodomains for lysine-methylated ARK(S/T) motifs," *Journal of Biological Chemistry*, vol. 283, no. 28, pp. 19626–19635, 2008.
- [123] S. Dorus, S. L. Gilbert, M. L. Forster, R. J. Barndt, and B. T. Lahn, "The CDY-related gene family: coordinated evolution in copy number, expression profile and protein sequence," *Human Molecular Genetics*, vol. 12, no. 14, pp. 1643–1650, 2003.
- [124] S. E. Kleiman, B. Bar-Shira Maymon, R. Hauser et al., "Histone H4 acetylation and AZFc involvement in germ cells of specimens of impaired spermatogenesis," *Fertility and Sterility*, vol. 89, no. 6, pp. 1728–1736, 2008.
- [125] P. H. Yen, "Putative biological functions of the DAZ family," *International Journal of Andrology*, vol. 27, no. 3, pp. 125–129, 2004.
- [126] N. Reynolds and H. J. Cooke, "Role of the DAZ genes in male fertility," *Reproductive BioMedicine Online*, vol. 10, no. 1, pp. 72–80, 2005.
- [127] E. Y. Xu, F. L. Moore, and R. A. Reijo-Pera, "A gene family required for human germ cell development evolved from an ancient meiotic gene conserved in metazoans," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 13, pp. 7414–7419, 2001.
- [128] R. Saxena, J. W. A. De Vries, S. Repping et al., "Four DAZ genes in two clusters found in the AZFc region of the human Y chromosome," *Genomics*, vol. 67, no. 3, pp. 256–267, 2000.
- [129] P. H. Yen, N. N. Chai, and E. C. Salido, "The human DAZ genes, a putative male infertility factor on the Y chromosome, are highly polymorphic in the DAZ repeat regions," *Mammalian Genome*, vol. 8, no. 10, pp. 756–759, 1997.
- [130] Y.-W. Lin, D. A. D. Thi, P.-L. Kuo et al., "Polymorphisms associated with the DAZ genes on the human Y chromosome," *Genomics*, vol. 86, no. 4, pp. 431–438, 2005.
- [131] B. Kim, Y. Lee, Y. Kim et al., "Polymorphic expression of DAZ proteins in the human testis," *Human Reproduction*, vol. 24, no. 6, pp. 1507–1515, 2009.
- [132] B. Habermann, H.-F. Mi, A. Edelmann et al., "DAZ (Deleted in AZoospermia) genes encode proteins located in human

- late spermatids and in sperm tails," *Human Reproduction*, vol. 13, no. 2, pp. 363–369, 1998.
- [133] R. A. Reijo, D. M. Dorfman, R. Slee et al., "DAZ family proteins exist throughout male germ cell development and transit from nucleus to cytoplasm at meiosis in humans and mice," *Biology of Reproduction*, vol. 63, no. 5, pp. 1490–1496, 2000.
- [134] W. J. Huang, Y.-W. Lin, K.-N. Hsiao, K. S. Eilber, E. C. Salido, and P. H. Yen, "Restricted expression of the human DAZ protein in premeiotic germ cells," *Human Reproduction*, vol. 23, no. 6, pp. 1280–1289, 2008.
- [135] R. Saxena, L. G. Brown, T. Hawkins et al., "The DAZ gene cluster on the human Y chromosome arose from an autosomal gene that was transposed, repeatedly amplified and pruned," *Nature Genetics*, vol. 14, no. 3, pp. 292–299, 1996.
- [136] A. I. Agulnik, A. Zharkikh, H. Boettger-Tong, T. Bourgeron, K. McElreavey, and C. E. Bishop, "Evolution of the DAZ gene family suggests that Y-linked DAZ plays little, or a limited, role in spermatogenesis but underlines a recent African origin for human populations," *Human Molecular Genetics*, vol. 7, no. 9, pp. 1371–1377, 1998.
- [137] Y. Lin and D. C. Page, "Dazl deficiency leads to embryonic arrest of germ cell development in XY C57BL/6 mice," *Developmental Biology*, vol. 288, no. 2, pp. 309–316, 2005.
- [138] T. Dai, Y. Vera, E. C. Salido, and P. H. Yen, "Characterization of the mouse Dazap I gene encoding an RNA-binding protein that interacts with infertility factors DAZ and DAZL," *BMC Genomics*, vol. 2, article 6, 2001.
- [139] S. Tsui, T. Dai, S. Roettger, W. Schempp, E. C. Salido, and P. H. Yen, "Identification of two novel proteins that interact with germ-cell-specific RNA-binding proteins DAZ and DAZL1," *Genomics*, vol. 65, no. 3, pp. 266–273, 2000.
- [140] J. Urano, M. S. Fox, and R. A. Reijo-Pera, "Interaction of the conserved meiotic regulators, BOULE (BOL) and PUMILIO-2 (PUM2)," *Molecular Reproduction and Development*, vol. 71, no. 3, pp. 290–298, 2005.
- [141] F. L. Moore, J. Jaruzelska, M. S. Fox et al., "Human Pumilio-2 is expressed in embryonic stem cells and germ cells and interacts with DAZ (Deleted in AZoospermia) and DAZ-like proteins," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 2, pp. 538–543, 2003.
- [142] F. L. Moore, J. Jaruzelska, D. M. Dorfman, and R. A. Reijo-Pera, "Identification of a novel gene, DZIP (DAZ-interacting protein), that encodes a protein that interacts with DAZ (deleted in azoospermia) and is expressed in embryonic stem cells and germ cells," *Genomics*, vol. 83, no. 5, pp. 834–843, 2004.
- [143] M. Ruggiu and H. J. Cooke, "In vivo and in vitro analysis of homodimerisation activity of the mouse Dazl1 protein," *Gene*, vol. 252, no. 1-2, pp. 119–126, 2000.
- [144] J. Z. Maines and S. A. Wasserman, "Post-transcriptional regulation of the meiotic Cdc25 protein Twine by the Dazl orthologue Boule," *Nature Cell Biology*, vol. 1, no. 3, pp. 171–174, 1999.
- [145] J. P. Venables, M. Ruggiu, and H. J. Cooke, "The RNA-binding specificity of the mouse Dazl protein," *Nucleic Acids Research*, vol. 29, no. 12, pp. 2479–2483, 2001.
- [146] S. Maegawa, M. Yamashita, K. Yasuda, and K. Inoue, "Zebrafish DAZ-like protein controls translation via the sequence 'GUUC,'" *Genes to Cells*, vol. 7, no. 9, pp. 971–984, 2002.
- [147] X. Jiao, P. Trifillis, and M. Kiledjian, "Identification of target messenger RNA substrates for the murine deleted in azoospermia-like RNA-binding protein," *Biology of Reproduction*, vol. 66, no. 2, pp. 475–485, 2002.
- [148] N. Reynolds, B. Collier, K. Maratou et al., "Dazl binds in vivo to specific transcripts and can regulate the pre-meiotic translation of Mvh in germ cells," *Human Molecular Genetics*, vol. 14, no. 24, pp. 3899–3909, 2005.
- [149] M. Zeng, W. Deng, X. Wang et al., "DAZL binds to the transcripts of several Tssk genes in germ cells," *Journal of Biochemistry and Molecular Biology*, vol. 41, no. 4, pp. 300–304, 2008.
- [150] K. Kee, V. T. Angeles, M. Flores, H. N. Nguyen, and R. A. Reijo-Pera, "Human DAZL, DAZ and BOULE genes modulate primordial germ-cell and haploid gamete formation," *Nature*, vol. 462, no. 7270, pp. 222–225, 2009.
- [151] B. Collier, B. Gorgoni, C. Loveridge, H. J. Cooke, and N. K. Gray, "The DAZL family proteins are PABP-binding proteins that regulate translation in germ cells," *EMBO Journal*, vol. 24, no. 14, pp. 2656–2666, 2005.
- [152] S. Tsui, T. Dai, S. T. Warren, E. C. Salido, and P. H. Yen, "Association of the mouse infertility factor DAZL1 with actively translating polyribosomes," *Biology of Reproduction*, vol. 62, no. 6, pp. 1655–1660, 2000.
- [153] K. H. Lee, S. Lee, B. Kim et al., "Dazl can bind to dynein motor complex and may play a role in transport of specific mRNAs," *EMBO Journal*, vol. 25, no. 18, pp. 4263–4270, 2006.
- [154] R. Slee, B. Grimes, R. M. Speed et al., "A human DAZ transgene confers partial rescue of the mouse Dazl null phenotype," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 14, pp. 8040–8045, 1999.
- [155] T. Vogel, R. M. Speed, A. Ross, and H. J. Cooke, "Partial rescue of the Dazl knockout mouse by the human DAZL gene," *Molecular Human Reproduction*, vol. 8, no. 9, pp. 797–804, 2002.
- [156] M. Feldkötter, V. Schwarzer, R. Wirth, T. F. Wienker, and B. Wirth, "Quantitative analyses of SMN1 and SMN2 based on real-time lightcycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy," *American Journal of Human Genetics*, vol. 70, no. 2, pp. 358–368, 2002.
- [157] S. Fernandes, S. Paracchini, L. H. Meyer, G. Floridia, C. Tyler-Smith, and P. H. Vogt, "A large AZFc deletion removes DAZ3/DAZ4 and nearby genes from men in Y haplogroup N," *American Journal of Human Genetics*, vol. 74, no. 1, pp. 180–187, 2004.
- [158] C. Geoffroy-Siraudin, I. Akinin-Seiffer, C. Metzler-Guillemain et al., "Meiotic abnormalities in patients bearing complete AZFc deletion of Y chromosome," *Human Reproduction*, vol. 22, no. 6, pp. 1567–1572, 2007.



**Hindawi**

Submit your manuscripts at  
<http://www.hindawi.com>

